Anti-Asthmatics And COPD Drugs Market Report 2026

Anti-Asthmatics And COPD Drugs Market Overview

• anti-asthmatics and COPD drugs market size has reached to $85.08 billion in 2025 • Expected to grow to $111.34 billion in 2030 at a compound annual growth rate (CAGR) of 5.7% • Growth Driver: Escalating Asthmatic Disorders Drives Growth In The Asthma And COPD Drugs Market • Market Trend: Technological Advancements in the Anti-Asthmatics and COPD Drugs Market to Enhance Environmentally Sustainable and Patient-Friendly Therapies • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Anti-Asthmatics And COPD Drugs Market?

Anti-asthmatic and chronic obstructive pulmonary disease drugs refer to drugs that are used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings. The main classes of drugs in anti-asthmatics and chronic obstructive pulmonary disease (COPD) are bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination drugs. A bronchodilator, also known as bronchiolitis, is a drug that stimulates the bronchi and bronchioles, reducing respiratory airway resistance and boosting lung airflow. The different types include anti-histamine drugs, long-acting β2-agonists (LABA), inhaled corticosteroids, short-acting muscarinic receptor antagonists (Samas), and other anti-asthmatics and COPD drugs (including combinations). The several end users include asthma patients, and COPD patients and are distributed through various channels such as hospital pharmacies, private clinics, drug stores, retail pharmacies, and e-commerce.

What Is The Anti-Asthmatics And COPD Drugs Market Growth Forecast?

The anti-asthmatics and copd drugs market size is expected to see strong growth in the next few years. It will grow to $111.34 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to advancements in biologics and monoclonal antibodies, integration of ai in treatment plans, increasing adoption of digital health solutions, expansion of online pharmacy channels, development of targeted therapies for severe copd. Major trends in the forecast period include personalized asthma management, telemedicine and remote patient monitoring, development of inhalable biologics, growing preference for combination therapies, focus on pediatric and geriatric formulations.

What Is The Driver Of The Anti-Asthmatics And COPD Drugs Market?

The high prevalence of asthmatic disorders is expected to propel the growth of the anti-asthmatics and COPD drugs market going forward. Asthma refers to a long-term disease that causes inflammation and swelling of the airways, resulting in the narrowing of the airways that carry air from the nose and mouth to the lungs. Owing to the increase in asthma cases, there has been a surge in the identification of new anti-asthmatics and COPD drugs for treating asthmatic disorders. For instance, June 2025, according to the Official Statistics, a UK-based government department, the rate of emergency admissions for asthma in adults (19+) increased by 17% in the financial year ending 2024, compared to the previous year. Therefore, the increasing number of asthmatic disorders leads to an increase in the development of novel drugs, which will further drive the asthma drug market.

Key Players In The Global Anti-Asthmatics And COPD Drugs Market

Major companies operating in the anti-asthmatics and copd drugs market are GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd, Lupin Limited, Abbott Laboratories, Pfizer, Vectura Group, Bayer, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Aspen Nigeria.

Global Anti-Asthmatics And COPD Drugs Market Trends and Insights

Major companies operating in the anti-asthmatics and COPD drugs market are focusing on technological advancements, such as next-generation propellant inhalers, to meet the rising demand for environmentally sustainable and patient-friendly respiratory therapies. Next-generation propellant technology replaces traditional hydrofluoroalkane (HFA) propellants with ones that have near-zero Global Warming Potential (GWP), reducing the carbon footprint of pressurized metered-dose inhalers (pMDIs) while maintaining drug delivery efficiency. For instance, in May 2025, AstraZeneca plc, a UK-based biopharmaceutical company, launched Trixeo Aerosphere, an innovative fixed-dose triple-combination therapy for COPD incorporating budesonide, glycopyrronium, and formoterol fumarate, now delivered via a next-generation propellant. This pMDI ensures bioequivalence to previous formulations, retains the established safety and efficacy profile, and offers a 99.9% reduction in GWP compared to traditional propellants. Trixeo Aerosphere supports sustainable healthcare practices without compromising clinical outcomes, providing an effective, low-carbon-footprint option for patients requiring inhaled respiratory therapy.

What Are Latest Mergers And Acquisitions In The Anti-Asthmatics And COPD Drugs Market?

In February 2024, GSK plc, a UK-based biopharmaceutical company, acquired Aiolos Bio for an amount of $1 billion. The acquisition of Aiolos with its AIO-001, boosts GSK’s respiratory portfolio by targeting severe asthma patients with low T2 inflammation. This strategic move positions GSK to expand its market reach and leadership in respiratory therapies while addressing a broader spectrum of asthma patients. Aiolos Bio is a US based biotechnology company specializes in developing treatments for respiratory and inflammatory conditions.

What Defines the Anti-Asthmatics And COPD Drugs Market?

The anti-asthmatic and chronic obstructive pulmonary disease market consists of corticosteroid, bronchodilator, fluticasone and salmeterol. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anti-Asthmatics And COPD Drugs Market Report 2026?

The anti-asthmatics and copd drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anti-asthmatics and copd drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.